Developing An Integrative Approach to Metastatic Prostate Cancer: Making it Personal to Improve Clinical Outcomes
- Educational Objectives
- Accreditation Info.
- Speaker List
- Request a Meeting
Until recently, there were few therapeutic options for patients with metastatic CRPC. However, in the past decade, the treatment landscape for CRPC has changed dramatically with the introduction of various agents with differing mechanisms of action that have demonstrated a survival benefit in CRPC.In the last five years, several new agents have received FDA approval for the treatment of CRPC, including novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce anti-tumor responses, new radiopharmaceuticals to target bony metastases, and novel chemotherapeutic agents.
With the approval of so many new agents in such a short period of time, clinicians are challenged to determine an optimal strategy to incorporate these therapies into practice. Since CRPC is such a heterogeneous disease, each patient presents individual challenges and without current evidence-based guidance for optimal sequencing and combinations of these therapies, clinicians are confronted with some vexing decisions. Optimizing these new therapeutic options for an individual patient remains elusive. It is unclear whether the best approach is sequential use of these agents or combination therapy.
This program will provide the most up-to-date information on recently completed and current clinical trials aimed at answering these important questions. Discussion on both existing and new treatment strategies will help healthcare providers to provide more informed treatment strategy decisions for their patients. Participants will also have the opportunity to discuss patient case studies with the presenter and their colleagues.
This Community Oncology Forum meeting series is designed to meet the educational needs of medical oncologists, surgical and radiation oncologists, urologists,and other healthcare professionals involved in the treatment of patients with metastatic prostate cancer.
1. Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, bone-targeted treatments and integration of chemotherapy
2. Assess appropriate strategies to integrate combined systemic therapeutic approachesin advanced prostatecancer
3. Formulate appropriate care plans based on individual patient disease characteristics and treatment related complications associated advanced prostate cancer
4. Understand factors that affect prognosis in patients with mCRPC
5. Formulate clinically appropriate approaches to discontinuation and sequencing of therapies based on best available evidence.
Rush University is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Rush University designates this live activity for one (1) Continuing Education credit(s).
This activity is being presented without bias and with commercial support.
This activity is sponsored by Rush University Office of Continuing Education, Prostate Conditions Education Council and Plexus Communications.
Charles Ryan, MD (Chair)
Professor of Clinical Medican and Urology, Department of Medicine, UCSF
Program Leader, Genitourinary Medical Oncology, UCSF
Neal Shore, MD, FACS
Atlantic Urology Clinics
Leonard Gomella, MD
Professor,Thomas Jefferson University
Department of Urology
Oliver Sartor, MD
Laborde Professor for Cancer Research
Medical Director Tulane Cancer Center
Nicklas Pfanzelter, MD
Assistant Professor, Rush University
Division of Hematology/Oncology
Ulka Vaishampayan, MD
Karmanos Cancer Center
William Oh, MD
Chief of the Division of Hematology and Medical Oncology, Professor of Medicine and Urology
The Mt. Sinai Hospital
Categories: Hospital Events